T he question posed in this debate dealt with the effectiveness of antidepressants rather than their efficacy. However, several of Dr Moncrieff's arguments are based on information gathered from randomized controlled trials (RCTs) of efficacy that often look at drug-placebo differences. Although that information is valuable, we urge readers to consider that effectiveness encompasses not only changes in overt symptoms but also improvements in quality of life, which Dr Moncrieff does not address.
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While Dr Moncrieff acknowledges that thousands of RCTs examine the efficacy of antidepressants, with many metaanalyses clearly showing their benefit, she summarily dismisses these findings, attributing them to publication bias and variability of methodology across trials. Her argument focuses on a single metaanalysis that supports a contrary position.
Dr Moncrieff suggests that evidence on sickness absence and suicide does not support an effect for antidepressants. We have already addressed the issue of antidepressants and work productivity, citing evidence of functional benefit for antidepressant therapies, but we agree that additional studies need to confirm these preliminary findings. With respect to suicide, Dr Moncrieff claims that abundant evidence shows that suicide trends are long-standing and not related to antidepressant prescribing patterns. Although this topic has engendered considerable controversy, there is clear evidence that the crude suicide rate in the United States has decreased over the last decade.
1,2 As well, after adjusting for unemployment and alcohol consumption, several authors have reported an association between reduction in suicide and increased antidepressant prescription rates in the United States, Sweden, Finland, Australia, and Hungary (reviewed in Grunebaum et al 2 ).
Dr Moncrieff suggests that antidepressants cause drug-induced states that coincidentally relieve depression, mainly through their sedating side effects. However, she disregards the growing evidence from functional neuroimaging studies-which we previously discussed-showing that regional brain abnormalities present in depression patients are often reversed when patients are treated with antidepressants but not when they are given placebo.
Dr Moncrieff also highlighted concerns about the original Hamilton Depression Rating Scale (HDRS), which have been raised by others. 3 Nevertheless, the HDRS consistently identifies 4 items with high sensitivity and predictive value in assessing change in depressive symptoms. 4 These items are depressed mood, guilt, work and interests, and psychic anxiety. Other nonspecific items, including sleep, appetite, and energy, contribute less to the measurement of change with antidepressants. In our opinion, it is hard to argue that these 4 items, commonly considered core depressive symptoms, would respond purely to the "nonspecific sedative effects of antidepressants."
What troubles us about Dr Moncrieff's position is that her arguments seem to suggest that, over the last 50 years, most in the psychiatric community have been repeatedly deceived by the pharmaceutical industry into prescribing medications with little or no effect for an illness with profound physical, social, and occupation sequelae. Although we agree that there is no magic bullet to cure depression, antidepressants play a significant role in its treatment, and to suggest they have no effect is tantamount to throwing the baby out with the bathwater.
